Cargando…
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322961/ https://www.ncbi.nlm.nih.gov/pubmed/25361008 |
_version_ | 1782356466087231488 |
---|---|
author | Fang, Wenfeng Zhang, Jianwei Hong, Shaodong Zhan, Jianhua Chen, Nan Qin, Tao Tang, Yanna Zhang, Yaxiong Kang, Shiyang Zhou, Ting Wu, Xuan Liang, Wenhua Hu, Zhihuang Ma, Yuxiang Zhao, Yuanyuan Tian, Ying Yang, Yunpeng Xue, Cong Yan, Yue Hou, Xue Huang, Peiyu Huang, Yan Zhao, Hongyun Zhang, Li |
author_facet | Fang, Wenfeng Zhang, Jianwei Hong, Shaodong Zhan, Jianhua Chen, Nan Qin, Tao Tang, Yanna Zhang, Yaxiong Kang, Shiyang Zhou, Ting Wu, Xuan Liang, Wenhua Hu, Zhihuang Ma, Yuxiang Zhao, Yuanyuan Tian, Ying Yang, Yunpeng Xue, Cong Yan, Yue Hou, Xue Huang, Peiyu Huang, Yan Zhao, Hongyun Zhang, Li |
author_sort | Fang, Wenfeng |
collection | PubMed |
description | PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients. |
format | Online Article Text |
id | pubmed-4322961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-43229612015-02-10 EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy Fang, Wenfeng Zhang, Jianwei Hong, Shaodong Zhan, Jianhua Chen, Nan Qin, Tao Tang, Yanna Zhang, Yaxiong Kang, Shiyang Zhou, Ting Wu, Xuan Liang, Wenhua Hu, Zhihuang Ma, Yuxiang Zhao, Yuanyuan Tian, Ying Yang, Yunpeng Xue, Cong Yan, Yue Hou, Xue Huang, Peiyu Huang, Yan Zhao, Hongyun Zhang, Li Oncotarget Research Paper PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane protein 1 (LMP1) and IFN-γ pathways cooperate to regulate programmed cell death protein 1 ligand (PD-L1). Expression of PD-L1 was higher in EBV positive NPC cell lines compared with EBV negative cell lines. PD-L1 expression could be increased by exogenous and endogenous induction of LMP1 induced PD-L1. In agreement, expression of PD-L1 was suppressed by knocking down LMP1 in EBV positive cell lines. We further demonstrated that LMP1 up-regulated PD-L1 through STAT3, AP-1, and NF-κB pathways. Besides, IFN-γ was independent of but synergetic with LMP1 in up-regulating PD-L1 in NPC. Furthermore, we showed that PD-L1 was associated with worse disease-free survival in NPC patients. These results imply that blocking both the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may be a promising therapeutic approach for EBV positive NPC patients. Impact Journals LLC 2014-10-21 /pmc/articles/PMC4322961/ /pubmed/25361008 Text en Copyright: © 2014 Fang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Fang, Wenfeng Zhang, Jianwei Hong, Shaodong Zhan, Jianhua Chen, Nan Qin, Tao Tang, Yanna Zhang, Yaxiong Kang, Shiyang Zhou, Ting Wu, Xuan Liang, Wenhua Hu, Zhihuang Ma, Yuxiang Zhao, Yuanyuan Tian, Ying Yang, Yunpeng Xue, Cong Yan, Yue Hou, Xue Huang, Peiyu Huang, Yan Zhao, Hongyun Zhang, Li EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy |
title | EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy |
title_full | EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy |
title_fullStr | EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy |
title_full_unstemmed | EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy |
title_short | EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy |
title_sort | ebv-driven lmp1 and ifn-γ up-regulate pd-l1 in nasopharyngeal carcinoma: implications for oncotargeted therapy |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322961/ https://www.ncbi.nlm.nih.gov/pubmed/25361008 |
work_keys_str_mv | AT fangwenfeng ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhangjianwei ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT hongshaodong ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhanjianhua ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT chennan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT qintao ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT tangyanna ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhangyaxiong ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT kangshiyang ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhouting ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT wuxuan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT liangwenhua ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT huzhihuang ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT mayuxiang ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhaoyuanyuan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT tianying ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT yangyunpeng ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT xuecong ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT yanyue ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT houxue ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT huangpeiyu ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT huangyan ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhaohongyun ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy AT zhangli ebvdrivenlmp1andifngupregulatepdl1innasopharyngealcarcinomaimplicationsforoncotargetedtherapy |